Real-world experience with daclatasvir plus sofosbuvir plus or minus ribavirin for post-liver transplant HCV recurrence and severe liver disease

Optimizing therapy of post-transplant HCV recurrence remains important, especially in advanced liver disease. We evaluated daclatasvir (DCV) plus sofosbuvir (SOF), with or without ribavirin (RBV), in patients with post-liver transplant recurrence in a real-world European cohort at high risk of decom...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Transplant international 2017-03, Vol.30 (3), p.243-255
Hauptverfasser:	Herzer, Kerstin, Welzel, Tania M, Spengler, Ulrich, Hinrichsen, Holger, Klinker, Hartwig, Berg, Thomas, Ferenci, Peter, Peck-Radosavljevic, Markus, Inderson, Akin, Zhao, Yue, Jimenez-Exposito, Maria Jesus, Zeuzem, Stefan
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!